Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf (CIO ABCD)

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer (2024) Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, et al. Journal article High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma (2024) Klümper N, Cox A, Eckstein M, Kuppe C, Ritter M, Brossart P, Luetkens J, et al. Journal article Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition (2024) Saal J, Bald T, Eckstein M, Ralser DJ, Brossart P, Ellinger J, Hölzel M, Klümper N Journal article On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. (2024) Saal J, Grünwald V, Bald T, Ritter M, Brossart P, Tomita Y, Hartmann A, et al. Journal article Membranous expression of target protein is required for ADC response in urothelial cancer (2024) Klümper N, Brägelmann J, Bahlinger V, Hartmann A, Grünwald V, Kuppe C, Hölzel M, Eckstein M Journal article Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance (2023) Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, Alajati A, et al. Journal article Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial (2023) Saal J, Bald T, Eckstein M, Ritter M, Brossart P, Ellinger J, Hoelzel M, Klümper N Journal article PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma (2023) Klümper N, Wüst L, Saal J, Ralser DJ, Zarbl R, Jarczyk J, Breyer J, et al. Journal article Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution (2023) Cox A, Klümper N, Stein J, Sikic D, Breyer J, Bolenz C, Roghmann F, et al. Journal article Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, et al. Conference contribution